Background
Substantial shortcomings in the quality of breast cancer (BC) care have been identified. While breast cancer is responsible for the largest share of cancer care spending, little is known about the value of care provided to US women with BC.
Methods
For women aged 65 to 70 years diagnosed July 1997 through December 2005 with stage 0-III BC who were continuously enrolled in fee-for-service Medicare, we evaluated performance relative to 20 measures recommending for proven therapies and seven measures recommending against unnecessary therapies. Using health care service area as the unit of analysis, we characterized quality for recommended and unnecessary therapies, median per-patient cost in the year after diagnosis for Medicare parts A and B, and five-year overall survival. We analyzed the relationships between quality, cost, and survival. All statistical tests were two-sided.
Results
We assessed the care provided to 15 357 women and compiled quality, cost, and outcomes data for 99 regions. The median number of patients/region was 85 (interquartile range = 47-158); the five-year overall survival was 87.5%. Part B expenditure correlated positively with measures of recommended therapy (P = .027) and negatively with measures of unnecessary therapy (P = .004). Survival did not correlate with quality or cost. Regions demonstrating lower quality for both recommended and unnecessary therapy measures exhibited higher part A expenditure.
Conclusions
BC patients experience wide variation in quality, cost, and survival. Process measures that assess recommended and unnecessary therapies did not correlate with survival, but did shed light on spending for related and unrelated services. Additional efforts to identify factors that impact the relationships between quality, cost, and outcomes are needed.
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Breast cancer, the most frequently diagnosed nondermatologic cancer among women, is responsible for approximately 40 000 deaths per year (1) . It is not surprising that spending for breast cancer care is substantial (2,3)-accounting for the largest share of cancer-related spending (4) . Despite this, some breast cancer patients fail to receive treatments known to be effective, such as radiation therapy and chemotherapy, and some experience inferior outcomes (5) (6) (7) . This has led to the suggestion that the value of breast cancer care may be suboptimal and that improving value should be the main focus of quality improvement efforts.
Value has been defined as health outcomes achieved per dollar spent (8) . Many believe that higher quality care will equate to higher value care, costing less with better outcomes. In an attempt to characterize value, a number of studies have explored the relationship between area-level measures of quality, health care spending, and patient outcomes. Most found that measures of quality were not associated with spending or outcomes (9) (10) (11) (12) (13) , whereas a few demonstrated that appropriate use of recommended therapy was associated with greater spending and improved outcomes (14, 15) .
While these analyses provide important insights, their applicability to cancer patients is unclear. Unlike many other conditions, cancer care is typically directed by a multidisciplinary team of specialists; cancer treatments incur substantial inpatient and outpatient expenditures, and concern regarding the overuse of costly cancer therapies is substantial. Unfortunately, few measures of cancer care value exist. Specifically, we are not aware of efforts to assess the relationship between quality and spending or to determine whether either is associated with improved outcomes for breast cancer patients.
We previously developed process measures for breast cancer based on consensus-and evidence-based clinical practice guidelines that evaluate both the appropriate use of recommended treatments and the inappropriate use of unnecessary treatments. Using these measures, we described the quality of care offered to patients treated at institutions participating in the National Comprehensive Cancer Network's (NCCN) outcomes database (5), and we demonstrated that these measures could be applied to patients using the Surveillance Epidemiology and End Results (SEER)/Medicare dataset (16) .
For this investigation, our goal was to use SEER/Medicare data to characterize the cost/quality relationship for a population-based sample of women with newly diagnosed stage 0-III breast cancer. Specifically, we wanted to determine whether higher quality breast cancer care was associated with less expenditure and better outcomes. Knowing that most early breast cancer treatments are delivered in the outpatient setting, but that inpatient services account for the largest proportion of cancer spending, we thought broad measures of quality and spending could be insensitive tools for assessing value. We also evaluated the independent relationships between measures of recommended/unnecessary therapies and spending for inpatient/outpatient services.
Methods

Data Source and Cohort
The SEER/Medicare database contains information on incident cancers for persons residing in SEER program areas linked to claims for Medicare enrollees. We identified women aged 65 to 70 years diagnosed July 1997 to December 2005 with pathologically confirmed, stage 0-III breast cancer. All were continuously enrolled in fee-for-service Medicare (parts A and B) from one year before to one year after their cancer diagnosis. Women were excluded if they were eligible for Medicare because of disability or end-stage renal disease, participated in a Medicare Advantage program, had another SEER cancer diagnosis, or were diagnosed with breast cancer based on a death certificate or autopsy.
Definitions of Variables and Quality Measures
Demographics and tumor characteristics were collected from SEER. Because SEER may underreport some definitive cancer treatments (17) , both SEER and Medicare claims were used to gather data on cancer treatments. Treatment variables included type of breast surgery, lymph node surgery, chemotherapy, and radiation therapy. Comorbidities in the year before diagnosis were identified using claims and scored using the method described by Charlson, Deyo, and Klabunde (18) (19) (20) . Vital status was derived from Medicare data.
We evaluated performance relative to 27 surgical, radiation, and chemotherapy quality measures based on recommendations made by NCCN (National Comprehensive Cancer Network) guidelines (21) . Because the measures evaluated performance relative to different aspects of care, patients could be assigned to more than one measure. The 27 measures were divided into two mutually exclusive groups: 20 assessed performance relative to recommendations for specific therapies (measures of underuse, such as failing to provide recommended radiation therapy), and seven assessed performance relative to recommendations against specific therapies (measures of overuse, such as providing chemotherapy when it is not recommended).
Expenditures were calculated using claims from Medicare parts A and B made during the year after diagnosis (to prevent duplicate counting, only claims with a record count of one were used). Part A includes inpatient hospital care, skilled nursing care, hospice, chemotherapy, and other services; part B includes doctors' fees, outpatient hospital visits, and other services/supplies not covered by part A. Most initial breast cancer services are reimbursed through part B, whereas the largest proportion of cancer spending is often attributed to part A. For each patient, we calculated part A, part B, and total expenditures (A + B). Expenditures were adjusted for inflation and expressed in 2010 US dollars (3).
Characterizing Regions
We assigned each patient to a health care service area (HSA) based on her place of residence when diagnosed with cancer. HSAsoriginally defined by the National Center for Health Statistics as individual counties or clusters of contiguous counties thought to be relatively self-contained with respect to health care-were modified by the National Cancer Institute for use with SEER. We selected HSA as the unit of analysis to encompass the multiple hospitaland clinic-based services offered to patients with newly diagnosed breast cancer. To ensure that each HSA had a sufficient number of patients to provide an accurate assessment of its performance, regions with fewer than 25 patients (22-24) were aggregated into one of four composite areas based on geography: northeast, south, midwest, and west.
Patient-level quality data were used to derive concordance values for each region using the overall percentage method described by Reeves and colleagues (14) , where concordance equals the number of patients who receive the recommended care divided by the number eligible for any measure. Three aggregate measures of concordance were calculated for each region: 1) overall concordance based on all 27 quality measures, 2) recommended-therapy concordance based on 20 underuse measures, and 3) unnecessarytherapy concordance based on seven overuse measures. Patientlevel expenditure data were used to derive median per-patient expenditures for each region. Three aggregate measures of spending were described: 1) total Medicare spending, 2) part A only, and 3) part B only. The five-year overall survival (OS) for all measureeligible patients was determined for each region.
Analyses
To evaluate the cost-quality relationship broadly, we grouped regions into spending quintiles based on their median total expenditure and compared overall concordance across spending quintiles. To determine whether measures assessing recommended and unnecessary therapies were related to spending for outpatient or inpatient services, we calculated Spearman correlations between each measure type and each spending type separately. For statistically significant correlations, we built a multivariate linear regression model to control for other factors. Other region-level predictors included mean patient age, the proportions of patients who were non-Hispanic white, had a comorbidity score ≥2, were in the lowest income quartiles, had a ≥T2 primary, had positive nodes, had hormone receptor (HR)-positive cancer, or had high-grade cancer.
It is intuitive to expect that process-based quality measures should correlate with spending for the services evaluated by these measures. We also wanted to explore whether these measures could be used to identify high spending on unrelated services. For each region, we determined whether the recommendedand unnecessary-therapy concordance values were above or below their corresponding medians, and we categorized regions into four groups: 1) quality greater than the median for recommended-and less than the median for unnecessary-therapy measures (more use regardless of the recommendation), 2) quality less than the median for recommended-and greater than the median for unnecessary-therapy measures (less use regardless of the recommendation), 3) quality less than the median for both (low quality for all), and 4) quality greater than the median for both (high quality for all). We evaluated spending and survival across these categories.
To evaluate the survival-spending and survival-quality relationships broadly, we defined quintiles based on spending and quality and described five-year OS across these quintiles. We also used correlations to test whether total spending or overall concordance was associated with survival.
Bivariable comparisons were made using sample means and the T-test or medians and the Wilcoxan rank sum test. The MantelHaenszel chi square test was used to assess trends across quintiles. Spearman correlation coefficients were used to characterize scatter plots comparing HSA-level characteristics. P less than .05 was considered statistically significant. Parameter estimates were reported with their 95% confidence intervals (CIs). Analyses were conducted using SAS version 9.1 (SAS Institute Inc., Cary, NC). All statistical tests were two-sided.
results
We identified 15 357 women with stage 0-III breast cancer who were eligible for at least one quality measure ( Table 1) . As expected, most were non-Hispanic white (81.7%), few had comorbidity scores of 2 or greater (7.4%), a majority had negative nodes (58.5%), and most had HR-positive disease (63.9%). Table 2 lists each quality measure with its number of eligible patients and overall concordance. The median number of eligible patients per measure was 529 (interquartile range [IQR] = 366-1700), and the median concordance was 76.9% (IQR = 64.5%-95.3%). Concordance relative to recommended-therapy measures was lower than concordance relative to nonrecommended therapy measures (median 73.4% vs 95.1%), but this difference was not statistically significant (P = .13). The five-year overall survival was 87.5%.
There were 94 HSAs with 25 or more eligible patient encounters. Only 4.5% of the cohort came from an HSA with less than 25 patients. Those for whom no HSA could be assigned were grouped into a separate region. In total 99 regions were defined, with a median of 85 eligible patients per region (IQR = 47-158). Regions demonstrated substantial variability in overall concordance, fiveyear survival, and median per patient expenditure (Figure 1 ). There were no statistically significant trends in overall concordance across spending quintiles, and there were no statistically significant trends in outcomes across either spending or quality quintiles (Figure 2) . After disaggregating quality and spending into their component parts, we found that median part B expenditure demonstrated a statistically significant positive correlation with recommendedtherapy concordance (Spearman correlation = 0.22, P = .027) and a statistically significant negative correlation with nonrecommended-therapy concordance (Spearman correlation = -0.29, P = .004) (Figure 3) . Concordance relative to recommended-and unnecessary-therapy measures did not correlate with each other (P = .36) (Figure 4 ) or with overall survival (P = .42). Two multivariate models were created to identify independent predictors of part B expenditures: one focused on concordance relative to recommended-therapy measures and the other on concordance relative to unnecessary-therapy measures. For each 1% increase in performance relative to recommended-therapy measures, part B expenditure increased $280 (95% CI = $104 to $456, P < .001). For each 1% increase in performance relative to nonrecommended-therapy measures part B expenditure decreased $136 (95% CI = $41 to $232, P < .001). Median part A expenditures were not correlated with either recommended or nonrecommended-therapy measure concordance (P = .56 and .44, respectively).
After classifying regions into four groups based on their performance relative to the median recommended-and unnecessarytherapy concordance values, we found that regions with quality less than the median for both demonstrated 22% greater part A expenditure than regions with quality more than the median for both; part B expenditures were similar ($22 004 vs $22 017) ( Figure 5 ; neither difference was statistically significant). Regions that provided less treatment regardless of the type of measure demonstrated the lowest part B expenditure (P ≤ .001) and the lowest five-year overall survival (NS).
Discussion
Our analysis of a large, population-based sample of women with newly diagnosed breast cancer identified substantial regional variation in quality, spending, and survival. Geographic variation in breast cancer care and outcomes have been described in national (25) and international (26) samples and have been associated with patient-level characteristics, such as socioeconomic status and race/ethnicity (27, 28) . We are not aware of previous efforts to evaluate the relationships between quality, spending, and outcomes for women with breast cancer. We found no statistically significant association between overall quality and total spending, and regional variation in survival was not explained by differences in overall quality or total spending. Previous studies of the relationships between quality, spending, and outcomes for patients with other conditions have yielded mixed results (9) (10) (11) (12) (13) (14) (15) (29) (30) (31) (32) , but more often have shown similar findings. There are several possible explanations for the lack of association between overall quality and total spending. Our analysis focused only on spending in the year after diagnosis. It may take years to realize the savings associated with higher quality initial cancer care (eg, chemotherapy now could prevent recurrence in five years). Our appraisal of total spending included many services that were not integral to providing the treatments evaluated by our measure set. It is impossible to know whether these unrelated services were simply unnecessary or important components of high quality care for other conditions. Our measure of overall quality included recommendations for proven treatments and against unnecessary treatments. If concordance with the former increased near-term spending and concordance with the latter decreased it, the net result could have been no apparent effect.
Believing that broad measures of quality and spending may be insensitive tools for identifying relevant associations and directing interventions, we separated quality into two categories (recommended vs unnecessary) and focused on their relationships with Medicare part B expenditures, because most initial breast cancer treatments are outpatient services (though chemotherapy can be covered by part A). After controlling for other factors, we found a positive relationship between recommended-therapy concordance and part B-expenditure and a negative relationship between unnecessary-therapy concordance and part B-expenditure.
A study of patients with lung and colorectal cancer also demonstrated that higher spending areas had higher rates of recommended care (33) . These findings are reassuring insofar as they support the validity of the measures as tools to evaluate service utilization. They also highlight that substantial Medicare part A spending masked the relationship between quality and outpatient spending, did not correlate with high-quality initial cancer care, and could represent an opportunity to reduce expenditures for breast cancer patients.
Interestingly, we did not see a correlation between measures recommending for treatment vs those recommending against it. Another study has identified a correlation between greater use of recommended therapy and greater use of nonrecommended therapy (15) . All of the measures in that study focused on one treatment modality (ie, chemotherapy), so it is not surprising that more appropriate use correlated with more unnecessary use. Our analysis evaluated multiple treatment modalities, so it may have provided a more general picture of a region's tendency toward increased ambulatory service utilization. The absence of a correlation between measures that address different treatment modalities, while common, confounds efforts to derive a simple metric of cancer care quality.
The lack of a statistically significant association between overall quality and outcomes is not surprising. Even though our analysis incorporated a broad set of measures that evaluated many aspects of breast cancer care, unmeasured factors could have had a substantial impact on patient outcomes. It is particularly challenging to establish a link between initial care quality and long-term outcomes for cancers that have a favorable prognosis (where outcomes occur years in the future and can be influenced by many other factors) and for cancers where treatments are predominantly palliative. Moreover, identifying a statistically significant relationship between care processes and outcomes using population-based data has technical challenges. Cancer treatments can have serious adverse effects, so there is often 3) less use of therapy regardless of the recommendation, and 4) lower quality relative to both for-and against-treatment measures. The Kruskal-Wallis test showed that only mean part B expenditure demonstrated statistically significant variation across the four groups (twosided P < .01).
bias in determining who receives therapy; currently available methods of adjusting for case-mix and confounding have substantial shortcomings.
Similar to other studies (11), we found no statistically significant association between total spending and overall survival. This suggests that breast cancer patients, like those with other medical conditions, receive many services that do not impact overall survival. While some of these services could be integral to achieving other relevant outcomes, such as quality of life, many are superfluous. The challenge is distinguishing between services that do or do not add value. For the reasons outlined above, analysis of the spendingoutcome relationship may not help much in this regard.
Evaluating care relative to measures of both recommended and nonrecommended services provides a potentially interesting paradigm for assessing value. We were able to highlight unnecessary processes that could have an immediate impact on spending. We found that regions demonstrating lower quality care relative to both measure types tended to demonstrate the greatest part A expenditures. Currently, a number of projects are trying to reduce health care spending by identifying regions that demonstrate higher-than-average inpatient expenditures. Our finding suggests that interventions to reduce inpatient expenditures may need to consider the quality of ambulatory services.
Our analysis has several limitations. The measures we selected, while relatively comprehensive, may not capture all aspects of the care provided within each region (eg, we were not able to assess concordance with hormone therapy recommendations). We did not adjust for regional variation in the cost of inputs, which if related to breast cancer quality could cause residual confounding. The study included spending during the first year after diagnosis; more work is needed to understand value across the full trajectory of care. In order to assess long-term outcomes, our cohort could not include patients diagnosed more recently. Since the sample was drawn from patients with fee-for-service Medicare, the ability to generalize our findings to younger patients and those covered by capitation-based plans is uncertain. A study that focuses on patients rather than service area as the unit of analysis would help to identify patient outliers regardless of where they reside. Multiple testing could have inflated the type I error.
Our findings help identify where improvement efforts could impact quality and spending, but they also highlight the need for more and better tools to measure value. Professional organizations have begun to establish guidelines for tests and procedures whose necessity should be questioned and discussed (34) . Developing quality measures around these guidelines will be an important next step. In addition to describing the appropriate use of recommended therapies and the inappropriate use of unnecessary therapies, it will be important to explore how the variable use of discretionary services relates to quality and spending. Most importantly, efforts that identify the system, patient, and disease factors that impact the relationship between quality, cost, and outcomes are critical for developing effective improvement strategies. 
